Literature DB >> 17652366

Systemic inflammation and remote organ injury following trauma require HMGB1.

Ryan M Levy1, Kevin P Mollen, Jose M Prince, David J Kaczorowski, Raghuveer Vallabhaneni, Shiguang Liu, Kevin J Tracey, Michael T Lotze, David J Hackam, Mitchell P Fink, Yoram Vodovotz, Timothy R Billiar.   

Abstract

High-mobility group box 1 (HMGB1) is a 30-kDa DNA-binding protein that displays proinflammatory cytokine-like properties. HMGB1-dependent inflammatory processes have been demonstrated in models of sterile injury, including ischemia-reperfusion injury and hemorrhagic shock. Here, we tested the hypothesis that the systemic inflammatory response and associated remote organ injury that occur after peripheral tissue injury are highly dependent on HMGB1. Toll-like receptor 4 (TLR4) wild-type (WT) mice subjected to bilateral femur fracture after treatment with neutralizing antibodies to HMGB1 had lower serum IL-6 and IL-10 levels compared with mice treated with nonimmune control IgG. Similarly, compared with injured mice treated with control IgG, anti-HMGB1 antibody-treated mice had lower serum alanine aminotransferase levels and decreased hepatic and gut mucosal NF-kappaB DNA binding. TLR4 mutant (C3H/HeJ) mice subjected to bilateral femur fracture had less systemic inflammation and liver injury than WT controls. Residual trauma-induced systemic inflammation and hepatocellular injury were not ameliorated by treatment with a polyclonal anti-HMGB1 antibody, even though HMGB1 levels were transiently elevated just 1 h after injury in both WT and C3H/HeJ mice. Collectively, these data demonstrate a critical role for a TLR4-HMGB1 pathway in the initiation of systemic inflammation and end-organ injury following isolated peripheral tissue injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652366     DOI: 10.1152/ajpregu.00272.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  105 in total

1.  Models of lower extremity damage in mice: time course of organ damage and immune response.

Authors:  Christoph L Menzel; Roman Pfeifer; Sophie S Darwiche; Philipp Kobbe; Roop Gill; Richard A Shapiro; Patricia Loughran; Yoram Vodovotz; Melanie J Scott; Mazen S Zenati; Timothy R Billiar; Hans-Christoph Pape
Journal:  J Surg Res       Date:  2010-12-23       Impact factor: 2.192

2.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

Review 3.  Phosphorylation mechanisms in intensive care medicine.

Authors:  Erica L Martin; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2010-09-04       Impact factor: 17.440

Review 4.  HMGB1 release by inflammasomes.

Authors:  Lieselotte Vande Walle; Thirumala-Dev Kanneganti; Mohamed Lamkanfi
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

5.  Dear SIRS, the concept of "alarmins" makes a lot of sense!

Authors:  Jérôme Pugin
Journal:  Intensive Care Med       Date:  2007-10-17       Impact factor: 17.440

Review 6.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

7.  Updates on Hepato-Renal Syndrome.

Authors:  Kyota Fukazawa; H Thomas Lee
Journal:  J Anesth Clin Res       Date:  2013-09-27

8.  Impact of intestinal ischemia/reperfusion and lymph drainage on distant organs in rats.

Authors:  Gui-Zhen He; Kai-Guo Zhou; Rui Zhang; Yu-Kang Wang; Xue-Feng Chen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 9.  Linking oxidative stress to inflammation: Toll-like receptors.

Authors:  Roop Gill; Allan Tsung; Timothy Billiar
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

10.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Alvin Denenberg; Basilia Zingarelli
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.